Patent intelligence · US
US 10596216
Use of a Withania extract for the treatment of amyloid-related diseases
Use of a Withania extract for the treatment of amyloid-related diseases
Patent details — US 10596216
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 24, 2020
- Expiration
- Mar 19, 2040
- Claims
- 18
- CPC classes
- A61K, A61K2236/19, A61K2236/39, A61K36/068
Quick answer
US 10596216 (Use of a Withania extract for the treatment of amyloid-related diseases) is held by Ethnodyne and Centre National de la Recherche Scientifique (CNRS). Status: granted. Granted Mar 24, 2020. Expires Mar 19, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K2236/19, A61K2236/39, A61K36/068, A61K36/185, A61K36/28
More from Ethnodyne and Centre National de la Recherche Scientifique (CNRS)
Related pharmaceutical patents in our USPTO index.
-
US 12428487
Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject
granted -
US 12403203
Muscle targeting complexes and uses thereof for treating dystrophinopathies
granted -
US 12397062
Muscle targeting complexes and uses thereof for treating dystrophinopathies
granted -
US 12370264
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
granted -
US 12357703
Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping
granted -
US 12329824
Muscle targeting complexes and uses thereof for treating dystrophinopathies
granted -
US 12329825
Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject
granted -
US 12325753
Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy
granted
Frequently asked questions
What is US patent 10596216?
US 10596216 (Use of a Withania extract for the treatment of amyloid-related diseases) is held by Ethnodyne and Centre National de la Recherche Scientifique (CNRS). Status: granted. Granted Mar 24, 2020. Expires Mar 19, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10596216?
Ethnodyne and Centre National de la Recherche Scientifique (CNRS) is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 82 pharmaceutical patents for this assignee.
When does US 10596216 expire?
Our index shows an expiration date of Mar 19, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.